Diabetes, Obesity and Metabolism Journal
Overview
Publication venue for
- Efficacy and safety ofiGlarLixiversusIDegLirain adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison 2020
- Impact of disease duration and beta-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial. 22:1567-1576. 2020
- Insulin glargine 300 U/mLversus first-generation basal insulin analogues in insulin-naive adults with type 2 diabetes: 12-month outcomes ofACHIEVEControl, a prospective, randomized, pragmatic real-life clinical trial 2020
- Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis 2020
- Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial. 22:929-937. 2020
- Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naive cohort study. 21:1596-1605. 2019
- Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3). 21:2384-2393. 2019
- Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. 20:921-929. 2018
- Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D plus cohort study. 20:2148-2158. 2018
- Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study. 20:1722-1731. 2018
- Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. 20:1293-1297. 2018
- Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials. 19:275-283. 2017
- Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme. 18:707-710. 2016
- Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy. 17. 2015
- Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. 14:20-32. 2012
- Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. 12:604-612. 2010
- Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. 11:978-986. 2009
- Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE(TM) study. 11:623-631. 2009
- The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. 11:26-34. 2009
Identity
International Standard Serial Number (ISSN)
- 1462-8902